Lexicon Pharmaceuticals (LXRX) Income from Continuing Operations (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Income from Continuing Operations of 5296000.0 for Q1 2026, up 81.51% year-over-year from 2917698.99 in Q1 2025, and up 68.5% quarter-over-quarter from 16811000.0 in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Income from Continuing Operations for 17 consecutive years, with 5296000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 81.51% year-over-year to 5296000.0; the TTM figure through Mar 2026 stood at 42966000.0 (up 77.51% YoY), while the FY2025 annual figure was 60556000.0, up 90.2% from the prior year.
- Income from Continuing Operations rose to 5296000.0 in Q1 2026 per LXRX's latest filing, from 16811000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4172000.0 in Q2 2025 and bottomed at 68255000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 34183235.29 across 5 years, with a median of 28647000.0 in 2025.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 146.74% — and 2025, when it jumped 92.75%.
- Lexicon Pharmaceuticals' Income from Continuing Operations stood at 25738000.0 in 2022, then sank by 106.2% to 53071000.0 in 2023, then surged by 31.05% to 36595000.0 in 2024, then jumped by 54.06% to 16811000.0 in 2025, then jumped by 68.5% to 5296000.0 in 2026.
- Business Quant data shows LXRX's Income from Continuing Operations at 5296000.0 in Q1 2026, 16811000.0 in Q4 2025, and 16687000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | -29.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.15 Mn |
| Mar 31, 2026 | -2.59 Mn |
| Dec 31, 2025 | -16.81 Mn |
| Sep 30, 2025 | -14.34 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | -27.51 Mn |
| Dec 31, 2024 | -36.60 Mn |
| Sep 30, 2024 | -68.26 Mn |
| Jun 30, 2024 | -57.57 Mn |
| Mar 31, 2024 | -50.28 Mn |
| Dec 31, 2023 | -52.16 Mn |
| Sep 30, 2023 | -53.53 Mn |
| Jun 30, 2023 | -46.14 Mn |
| Mar 31, 2023 | -32.70 Mn |
| Dec 31, 2022 | -31.32 Mn |
| Sep 30, 2022 | -24.30 Mn |
| Jun 30, 2022 | -24.82 Mn |
| Mar 31, 2022 | -23.52 Mn |
| Dec 31, 2021 | -25.63 Mn |
| Sep 30, 2021 | -23.13 Mn |